Inventor · disambiguated record
Terence A. Kelly
Also filed as: KELLY TERENCE · KELLY TERENCE A · KELLY TERENCE ALFRED
27 granted patents·8 pending applications·425 citations·filing 1994–2024
97Inventor score
Files withBOEHRINGER INGELHEIM PHARMA17INHIBIKASE THERAPEUTICS INC9CYTOSITE BIOPHARMA INC3ALLOCYTE PHARMACEUTICALS AG2PERCEPTION NEUROSCIENCE INC2
Top patents by PatentIndex Score
35 records- 0195US6350763B1Small molecules useful in the treatment of inflammation diseaseBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Feb 26, 2002·51 cites·6 claims
- 0293US11407747B2Compositions and methods for inhibiting kinasesINHIBIKASE THERAPEUTICS INC·Filed 2021·Granted Aug 9, 2022·2 cites·20 claims
- 0392US10906896B2Compositions and methods for inhibiting kinasesINHIBIKASE THERAPEUTICS INC·Filed 2019·Granted Feb 2, 2021·3 cites·20 claims
- 0492US6689804B2Small molecules useful in the treatment of inflammatory diseaseBOEHRINGER INGELHEIM PHARMA·Filed 2002·Granted Feb 10, 2004·46 cites·5 claims
- 0591US9828370B2Compositions and methods for inhibiting kinasesINHIBIKASE THERAPEUTICS INC·Filed 2016·Granted Nov 28, 2017·7 cites·19 claims
- 0690US10118923B2Compositions and methods for inhibiting kinasesINHIBIKASE THERAPEUTICS INC·Filed 2017·Granted Nov 6, 2018·6 cites·13 claims
- 0789US10344027B2Compositions and methods for inhibiting kinasesINHIBIKASE THERAPEUTICS INC·Filed 2018·Granted Jul 9, 2019·4 cites·8 claims
- 0889US6492408B1Small molecules useful in the treatment of inflammatory diseaseBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Dec 10, 2002·35 cites·11 claims
- 0989US6414153B11-phenylpydrrolidin-2-ones and -thiones and 1-(4-pyridyl)pydrrolidin-2-ones and -thiones which are useful in the treatment of inflammatory diseaseBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Jul 2, 2002·40 cites·14 claims
- 1089US6365615B1Small molecules useful in the treatment of inflammatory diseaseBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Apr 2, 2002·22 cites·4 claims
- 1189US2025250266A1Compositions and methods for inhibiting kinasesINHIBIKASE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1288US6844360B2Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamideBOEHRINGER INGELHEIM PHARMA·Filed 2003·Granted Jan 18, 2005·24 cites·11 claims
- 1388US5532358AMethod for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-onesBOEHRINGER INGELHEIM PHARMA·Filed 1994·Granted Jul 2, 1996·35 cites·6 claims
- 1487US7304067B2Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamideBOEHRINGER INGELHEIM PHARMA·Filed 2005·Granted Dec 4, 2007·8 cites·7 claims
- 1587US6720293B2Low viscosity lubricating oil compositionsINFINEUM INT LTD·Filed 2001·Granted Apr 13, 2004·32 cites·11 claims
- 1686US6852748B1Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amideBOEHRINGER INGELHEIM PHARMA·Filed 2003·Granted Feb 8, 2005·24 cites·17 claims
- 1786US6355664B1Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory diseaseBOEHRINGER INGELHEIM PHARMA·Filed 1999·Granted Mar 12, 2002·46 cites·12 claims
- 1884US10316031B2Compositions and methods for inhibiting kinasesINHIBIKASE THERAPEUTICS INC·Filed 2018·Granted Jun 11, 2019·2 cites·8 claims
- 1982US11725005B2Compositions and methods for inhibiting kinasesINHIBIKASE THERAPEUTICS INC·Filed 2022·Granted Aug 15, 2023·0 cites·1 claims
- 2082US7589115B2Derivatives of [6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-sulfonylamino]-propionamideBOEHRINGER INGELHEIM PHARMA·Filed 2007·Granted Sep 15, 2009·4 cites·9 claims
- 2179US7345074B2Derivatives of [6,7-dihydro-5H-imidazol[1,2-a]imidazole-3-sulfonylamino]-propionamideBOEHRINGER INGELHEIM PHARMA·Filed 2004·Granted Mar 18, 2008·8 cites·4 claims
- 2274US6353013B1Small molecules useful in the treatment of inflammatory diseaseBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Mar 5, 2002·7 cites·15 claims
- 2373US7462637B2Derivatives of [6,7-dihydro-5H-imidazo[1,2--a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amideBOEHRINGER INGELHEIM PHARMA·Filed 2004·Granted Dec 9, 2008·6 cites·8 claims
- 2471US10077238B2Small molecule LFA-1 inhibitorsALLOCYTE PHARMACEUTICALS AG·Filed 2015·Granted Sep 18, 2018·4 cites·18 claims
- 2570US7550494B2Small molecules useful in the treatment of inflammatory diseaseBOEHRINGER INGELHEIM PHARMA·Filed 2003·Granted Jun 23, 2009·5 cites·21 claims
- 2666US2023257388A1Granzyme b directed imaging and therapyCYTOSITE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 2756USRE38132EPhenylpyrrolidines, phenylimidazolidines,3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory diseaseBOEHRINGER INGELHEIM PHARMA·Filed 2002·Granted Jun 3, 2003·1 cites·14 claims
- 2854US2025195412A1Pharmaceutical formulations of r-ketaminePERCEPTION NEUROSCIENCE INC·Filed 2023·Application pending·0 cites
- 2952US2024336556A1R-ketamine salts and methods of use thereofPERCEPTION NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 3047US11667645B2Granzyme B directed imaging and therapyCYTOSITE BIOPHARMA INC·Filed 2019·Granted Jun 6, 2023·0 cites·14 claims
- 3146US2020046699A1Compositions and methods for inhibiting kinasesINHIBIKASE THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3244US5837704A2-heteroaryl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-E! 1,4!diazepines and their use in the prevention or treatment of HIV infectionBOEHRINGER INGELHEIM PHARMA·Filed 1995·Granted Nov 17, 1998·3 cites·7 claims
- 3344US2023132386A9Granzyme b directed imaging and therapyCYTOSITE BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 3439US2019040008A1Small molecule lfa-1 inhibitorsALLOCYTE PHARMACEUTICALS AG·Filed 2018·Application pending·0 cites
- 3538US2003008848A1Small molecules useful in the treatment of inflammatory diseaseFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Terence A. Kelly files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →